University of Kansas Medical Center (KUMC)

#Biotechnology #Concussion #Neurology #Neuroscience #Oxeia Biopharmaceuticals #University of Kansas Medical Center (KUMC)

“Game changing” concussion drug study shows positive early results  

Oxeia Biopharmaceuticals, a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, has announced “game-changing” results of a Phase IIa pilot study of OXE103 at the University of Kansas Medical Center (KUMC).   The study results suggest a potentially… Read More

#News